{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:19:59Z","timestamp":1790126399227,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijid.2024.01.023","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T22:02:17Z","timestamp":1709589737000},"page":"106956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options\u2014the ICONA Foundation cohort study"],"prefix":"10.1016","volume":"143","author":[{"given":"Sergio","family":"Lo Caputo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-489X","authenticated-orcid":false,"given":"Mariacristina","family":"Poliseno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-451X","authenticated-orcid":false,"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"d'Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cozzi-Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.01.023_bib0001","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increased life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2024.01.023_bib0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/COH.0000000000000298","article-title":"Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with the general population","volume":"11","author":"Wandeler","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0003","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32805e8764","article-title":"Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients","volume":"21","author":"Napravnik","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0004","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1371\/journal.pmed.0030356","article-title":"Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART","volume":"3","author":"Hogg","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2024.01.023_bib0005","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/01.aids.0000131339.68666.1a","article-title":"Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing","volume":"18","author":"Lucas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/aje\/kwq101","article-title":"Epidemiology of antiretroviral multiclass resistance","volume":"172","author":"Lima","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijid.2024.01.023_bib0007","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(07)61815-7","article-title":"Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study","volume":"370","author":"Phillips","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.01.023_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12879-023-08038-w","article-title":"Heavily treatment-experienced people living with HIV in the OPERA\u00ae cohort: population characteristics and clinical outcomes","volume":"23","author":"Hsu","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2024.01.023_bib0009","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14787210.2021.1865801","article-title":"Fostemsavir for the treatment of HIV","volume":"19","author":"Seval","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2024.01.023_bib0010","doi-asserted-by":"crossref","first-page":"e00110","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2024.01.023_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0012","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","article-title":"Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options","volume":"34","author":"Bajema","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0013","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/QAI.0000000000002635","article-title":"Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort","volume":"87","author":"Pelchen-Matthews","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2024.01.023_bib0014","doi-asserted-by":"crossref","first-page":"ofab562","DOI":"10.1093\/ofid\/ofab562","article-title":"Characterization of heavily treatment-experienced people with HIV and impact on health care resource utilization in US commercial and medicare advantage health plans","volume":"8","author":"Priest","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2024.01.023_bib0015","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1097\/00002030-200311070-00014","article-title":"Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997\u20132002) based on an analysis of over 7000 genotypes","volume":"17","author":"Tamalet","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0016","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1086\/432763","article-title":"Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom","volume":"192","author":"Pillay","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2024.01.023_bib0017","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3851\/IMP1412","article-title":"The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999\u20132005","volume":"14","author":"Audelin","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2024.01.023_bib0018","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/QAD.0000000000001967","article-title":"Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort","volume":"32","author":"Pelchen-Matthews","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2024.01.023_bib0019","unstructured":"ICONA Foundation. Available at: www.fondazioneICONA.org-; 2022 [accessed 04 November 2022]."},{"key":"10.1016\/j.ijid.2024.01.023_bib0020","doi-asserted-by":"crossref","first-page":"999","DOI":"10.7326\/0003-4819-124-11-199606010-00008","article-title":"Survivor treatment selection bias in observational studies: examples from the AIDS literature","volume":"124","author":"Glesby","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2024.01.023_bib0021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep4.1112","article-title":"Human immunodeficiency virus and liver disease: a comprehensive update","volume":"1","author":"Sherman","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ijid.2024.01.023_bib0022","doi-asserted-by":"crossref","first-page":"21487","DOI":"10.7448\/IAS.19.8.21487","article-title":"Are HIV\/HCV coinfected patients more likely to experience multiple lines of ART than HIV monoinfected patients? International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK","volume":"19","author":"Marchetti","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijid.2024.01.023_bib0023","doi-asserted-by":"crossref","first-page":"e47506","DOI":"10.1371\/journal.pone.0047506","article-title":"Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the Insight STALWART Study","volume":"7","author":"Markowitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2024.01.023_bib0024","first-page":"15","article-title":"Implications of the SILCAAT and Esprit trials and the future for HIV immunotherapy","volume":"15","author":"Peters","year":"2010","journal-title":"J HIV Ther"},{"key":"10.1016\/j.ijid.2024.01.023_bib0025","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2024.01.023_bib0026","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.clinthera.2022.04.007","article-title":"Comparative efficacy and safety of fostemsavir in heavily treatment-experienced people with HIV-1","volume":"44","author":"Anderson","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2024.01.023_bib0027","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with Lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2024.01.023_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s10461-023-04088-y","article-title":"Impact of HIV on COVID-19 outcomes: a propensity score matching analysis with varying age differences","author":"Guo","year":"2023","journal-title":"AIDS Behav"},{"key":"10.1016\/j.ijid.2024.01.023_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijid.2023.09.015","article-title":"Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network","volume":"136","author":"Giacomelli","year":"2023","journal-title":"Int J Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T03:00:41Z","timestamp":1715742041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"alternative-id":["S1201971224000249"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.01.023","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options\u2014the ICONA Foundation cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"106956"}}